Treatment(s) already received-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological therapy Posts on Medivizor

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Posted by on Aug 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Posted by on Oct 17, 2021 in Breast cancer | 0 comments

In a nutshell The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients.  Some background Breast cancer (BC) is the most common tumor in women...

Read More

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...

Read More

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between pyrotinib (SHR-1258) and trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2+ metastatic breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data showed that pyrotinib may be more effective than T-DM1 for these patients. Some...

Read More

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...

Read More

Ending trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission

Ending trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission

Posted by on Oct 20, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission.   This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...

Read More

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor